Arcus BiosciencesRCUS
RCUS
About: Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Employees: 577
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
72% more call options, than puts
Call options by funds: $3.79M | Put options by funds: $2.2M
2% more capital invested
Capital invested by funds: $798M [Q2] → $814M (+$16.4M) [Q3]
0.62% more ownership
Funds ownership: 57.62% [Q2] → 58.24% (+0.62%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
4% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 70
4% less funds holding
Funds holding: 193 [Q2] → 185 (-8) [Q3]
27% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 30
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
29%
upside
Avg. target
$27
74%
upside
High target
$30
94%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target | 29%upside $20 | Neutral Reiterated | 6 Nov 2024 |
Barclays Peter Lawson 12% 1-year accuracy 3 / 26 met price target | 87%upside $29 | Overweight Maintained | 25 Oct 2024 |
Wells Fargo Eva Fortea Verdejo 40% 1-year accuracy 2 / 5 met price target | 87%upside $29 | Overweight Initiated | 8 Oct 2024 |
Wedbush Robert Driscoll 20% 1-year accuracy 13 / 65 met price target | 94%upside $30 | Outperform Reiterated | 3 Oct 2024 |
Financial journalist opinion
Based on 3 articles about RCUS published over the past 30 days
Neutral
Business Wire
2 days ago
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Tuesday, January 14th, 2025, at 3:45pm PT. A live webcast of the presentation will be avail.
Neutral
Business Wire
1 week ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 7,400 shares of the Company's common stock at an exercise price per share of $17.47 which was the closing price on December 9, 2024, and.
Neutral
Business Wire
2 weeks ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,000 shares of the Company's common stock at an exercise price per share of $14.56, which was the closing price on November 25, 2024,.
Neutral
Business Wire
1 month ago
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7th Annual HealthCONx Conference Date: Tuesday, December 3rd, 2024 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 7:55 a.m. ET Citi 2024.
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company's common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and.
Negative
Zacks Investment Research
1 month ago
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.94 per share a year ago.
Neutral
Business Wire
1 month ago
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules — targeting TIGIT, HIF-2a, CD73, the A2a/A2b receptors, CD-39, AXL and PD-1 — across multiple common cancers. “Through.
Neutral
Business Wire
1 month ago
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, (DZ) versus zimberelimab (Z) or chemotherapy in patients with fron.
Negative
Zacks Investment Research
1 month ago
Analysts Estimate Arcus Biosciences, Inc. (RCUS) to Report a Decline in Earnings: What to Look Out for
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 month ago
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced four accepted abstracts at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Houston, Texas, November 6 – 10, 2024. A late-breaking poster presented by Melissa L. Johnson, M.D., director, lung cancer research, Sarah Cannon Research I.
Charts implemented using Lightweight Charts™